Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial tested MK-3475 — a type of immunotherapy — before surgery for head and neck squamous cell carcinoma, and it's now completed; can you tell me what the results showed about whether the tumor responded to treatment before surgery, and whether that would be relevant to my situation?
2. 2The trial measured something called a 'major pathologic treatment effect,' which means how much the tumor shrinks or changes by the time of surgery — how significant is that kind of response, and what would it mean for my long-term outlook if I responded well or didn't respond at all?
3. 3Since this was a Phase 2 trial and it's now completed, does the data provide enough evidence to change how you'd approach my treatment, or would you still consider standard surgery with or without chemotherapy and radiation to be the safer, better-established path for me?
4. 4The trial tracked both locoregional recurrence — meaning the cancer coming back nearby — and distant failure, meaning spread to other parts of the body; based on what the trial found, does adding immunotherapy before surgery appear to reduce either of those risks compared to standard treatment?
5. 5This trial required patients to receive immunotherapy before surgery, which adds steps and time to the treatment process — if you thought this approach was worth considering for me, how would that affect my overall treatment timeline and what logistical demands should I be prepared for?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.